Arvinas (ARVN) Capital Expenditures Growth (1y) (2018 - 2026)
Powered by 
Analysis
Arvinas (ARVN) Capital Expenditures Growth (1y) (2018 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | -22.99% |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 9.68% |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 1,133.33% |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | -37.81% |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 142.64% |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 22,433.30% |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -73.62% |
| 10 | Arvinas | 605.56 Mn | 37.66 Mn | - | -83.33% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -83.33% |
| Mar 31, 2026 | 225.00% |
| Dec 31, 2025 | -33.33% |
| Sep 30, 2025 | -85.71% |
| Jun 30, 2025 | 71.43% |
| Mar 31, 2025 | 300.00% |
| Dec 31, 2024 | 200.00% |
| Sep 30, 2024 | -36.36% |
| Jun 30, 2024 | 16.67% |
| Mar 31, 2024 | -90.91% |
| Dec 31, 2023 | -90.91% |
| Sep 30, 2023 | -50.00% |
| Jun 30, 2023 | -57.14% |
| Mar 31, 2023 | -47.62% |
| Dec 31, 2022 | -42.11% |
| Sep 30, 2022 | 69.23% |
| Jun 30, 2022 | 180.00% |
| Mar 31, 2022 | 110.00% |
| Dec 31, 2021 | 5.14% |
| Sep 30, 2021 | -7.59% |